NC
FDMT icon

nVerses Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

nVerses Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,069
Closed -$93.7K – 382
2026
Q1 		$93.7K Buy
+10,069
New +$87.6K 0.09% 328
2024
Q4 		– Sell
-3,700
Closed -$40K – 297
2024
Q3 		$40K Buy
+3,700
New +$61.4K 0.02% 693

Other funds holding FDMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

nVerses Capital's FDMT Position: Q2 2026 in Review

nVerses Capital sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 10,069 shares — an estimated $93.7K sold.

nVerses Capital first reported a position in FDMT in Q3 2024 and held it in 2 quarters. The position peaked at $93.7K in Q1 2026. 100 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • nVerses Capital reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 10,069 4D Molecular Therapeutics shares in Q2 2026, an estimated $93.7K.
  • nVerses Capital first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's 4D Molecular Therapeutics position peaked at $93.7K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.